Free Trial
NASDAQ:IDXX

IDEXX Laboratories (IDXX) Stock Price, News & Analysis

IDEXX Laboratories logo
$531.32 +3.54 (+0.67%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$533.12 +1.80 (+0.34%)
As of 07:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About IDEXX Laboratories Stock (NASDAQ:IDXX)

Key Stats

Today's Range
$526.50
$535.20
50-Day Range
$406.65
$531.32
52-Week Range
$356.14
$535.20
Volume
624,759 shs
Average Volume
643,182 shs
Market Capitalization
$42.73 billion
P/E Ratio
49.11
Dividend Yield
N/A
Price Target
$546.00
Consensus Rating
Moderate Buy

Company Overview

IDEXX Laboratories, Inc., founded in 1983 and headquartered in Westbrook, Maine, is a leading provider of diagnostic and information technology-based products and services for the animal health, water testing and dairy markets. Originally established to develop rapid diagnostic tests for companion animals, the company has expanded its portfolio through both innovation and strategic acquisitions. Over the decades, IDEXX has grown into a diversified life sciences company, leveraging proprietary technologies to deliver actionable insights to its customers.

In the animal health segment, IDEXX offers a comprehensive suite of in-clinic diagnostic instruments, consumables and digital imaging solutions. Key products include the SNAP® family of rapid immunoassays, Catalyst® chemistry analyzers, ProCyte® hematology systems and sophisticated imaging equipment that enable veterinarians to perform a wide range of tests—from routine blood panels and disease screening to advanced imaging for soft tissue and orthopedic evaluation. The company also provides practice management software and telehealth services designed to streamline clinic operations and enhance patient care.

Beyond veterinary diagnostics, IDEXX serves the water quality and dairy industries. Its water microbiology business offers reagents, instruments and data management tools to detect pathogens and monitor water safety in municipal, recreational and industrial settings. In the dairy sector, IDEXX supplies tests for mastitis detection, antibiotics screening and herd health monitoring, helping producers maintain milk quality and comply with regulatory standards. The company’s emphasis on rapid, accurate results supports public health initiatives and food safety programs worldwide.

With operations in more than 175 countries, IDEXX maintains a global network of R&D centers, manufacturing facilities and distribution channels. The company is led by President and Chief Executive Officer Jonathan W. Ayers, who has overseen continued investment in innovation, expanded service offerings and international growth since 2018. Under his leadership, IDEXX remains focused on delivering cutting-edge diagnostics and data-driven solutions that empower customers to make timely, informed decisions.

AI Generated. May Contain Errors.

IDEXX Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
73rd Percentile Overall Score

IDXX MarketRank™: 

IDEXX Laboratories scored higher than 73% of companies evaluated by MarketBeat, and ranked 276th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    IDEXX Laboratories has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    IDEXX Laboratories has only been the subject of 3 research reports in the past 90 days.

  • Read more about IDEXX Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for IDEXX Laboratories are expected to grow by 13.83% in the coming year, from $11.93 to $13.58 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of IDEXX Laboratories is 49.11, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.88.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of IDEXX Laboratories is 49.11, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.24.

  • Price to Earnings Growth Ratio

    IDEXX Laboratories has a PEG Ratio of 3.88. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    IDEXX Laboratories has a P/B Ratio of 27.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about IDEXX Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.19% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 1.17%, indicating that investor sentiment is improving.
  • Dividend Yield

    IDEXX Laboratories does not currently pay a dividend.

  • Dividend Growth

    IDEXX Laboratories does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.19% of the float of IDEXX Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    IDEXX Laboratories has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in IDEXX Laboratories has recently decreased by 1.17%, indicating that investor sentiment is improving.
  • News Sentiment

    IDEXX Laboratories has a news sentiment score of 1.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for IDEXX Laboratories this week, compared to 17 articles on an average week.
  • Search Interest

    Only 5 people have searched for IDXX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, IDEXX Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,182,920.00 in company stock.

  • Percentage Held by Insiders

    Only 0.98% of the stock of IDEXX Laboratories is held by insiders.

  • Percentage Held by Institutions

    87.84% of the stock of IDEXX Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about IDEXX Laboratories' insider trading history.
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

IDXX Stock News Headlines

Trump’s unwinnable war
Over the years, we’ve been dragged into a long line of wars. The war on drugs. The war on terror. Wars with no clear goal, no endgame… no real answers for why we were fighting them in the first place. Trillions spent, countless young lives lost, and what do we have to show for it? And now, as yet another conflict erupts in the Middle East and billions more are burned in foreign sand, I urge you: Do not be distracted.
See More Headlines

IDXX Stock Analysis - Frequently Asked Questions

IDEXX Laboratories' stock was trading at $413.44 at the beginning of the year. Since then, IDXX stock has increased by 28.5% and is now trading at $531.32.
View the best growth stocks for 2025 here
.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings results on Thursday, May, 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The firm's quarterly revenue was up 3.6% on a year-over-year basis.
Read the conference call transcript
.

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that IDEXX Laboratories investors own include Tesla (TSLA), Broadcom (AVGO), Applied Materials (AMAT), HubSpot (HUBS), ASML (ASML), CrowdStrike (CRWD) and Cadence Design Systems (CDNS).

Company Calendar

Last Earnings
5/01/2025
Today
6/30/2025
Next Earnings (Confirmed)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:IDXX
Employees
10,800
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$546.00
High Stock Price Target
$580.00
Low Stock Price Target
$510.00
Potential Upside/Downside
+2.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
49.11
Forward P/E Ratio
44.54
P/E Growth
3.88
Net Income
$887.87 million
Pretax Margin
28.60%

Debt

Sales & Book Value

Annual Sales
$3.90 billion
Cash Flow
$12.43 per share
Price / Cash Flow
42.75
Book Value
$19.48 per share
Price / Book
27.28

Miscellaneous

Free Float
79,634,000
Market Cap
$42.73 billion
Optionable
Optionable
Beta
1.55

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:IDXX) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners